Results 211 to 220 of about 26,368 (251)
Some of the next articles are maybe not open access.
Gemcitabine/nab‐paclitaxel for pediatric relapsed/refractory sarcomas
Pediatric Blood & Cancer, 2018AbstractBackgroundPediatric patients with relapsed/refractory sarcomas have poor outcomes and need novel therapies that provide disease control while maintaining an acceptable quality of life. The activity and toxicity of gemcitabine and nab‐paclitaxel in combination has not been reported in pediatrics.ProcedureWe reviewed the records of fifteen ...
Jonathan L. Metts +7 more
openaire +2 more sources
nab-Paclitaxel mechanisms of action and delivery
Journal of Controlled Release, 2013Taxanes are a key chemotherapy component for several malignancies, including metastatic breast cancer (MBC), ovarian cancer, and advanced non-small cell lung cancer (NSCLC). Despite the clinical benefit achieved with solvent-based (sb) taxanes, these agents can be associated with significant and severe toxicities.
openaire +2 more sources
Efficacy of nab-paclitaxel in treating metastatic melanoma
Expert Opinion on Pharmacotherapy, 2019Systemic treatment of metastatic melanoma has been revolutionized by the advent of checkpoint inhibitors and targeted agents which are widely accepted as standard front-line therapies. However, despite these major advances, a substantial portion of patients still fail checkpoint inhibitors and/or targeted agents and are not candidates for clinical ...
openaire +3 more sources
Gemcitabine and nab-paclitaxel induced interstitial pneumonia
Diagnostic and Interventional Imaging, 2021Claire Sabat +2 more
openaire +2 more sources